<?xml version="1.0" encoding="UTF-8"?>
<p>Mycophenolate mofetil (MMF) is an oral inhibitor of 
 <italic>de novo</italic> purine synthesis in lymphocytes, and is prescribed for a variety of approved and off-label indications in rheumatology, such as SLE, ANCA-associated vasculitides (AAV), scleroderma, etc. No clear association between MMF administration and HBVr has been identified so far. Interestingly, earlier 
 <italic>in vitro</italic> data supported an inhibitive effect of MMF on replication of several viruses, HBV included,
 <sup>
  <xref rid="bibr38-1759720X20912646" ref-type="bibr">38</xref>,
  <xref rid="bibr39-1759720X20912646" ref-type="bibr">39</xref>
 </sup> whereas other clinical studies in solid organ transplant recipients exhibited neutral impact of MMF on HBV replication.
 <sup>
  <xref rid="bibr40-1759720X20912646" ref-type="bibr">40</xref>,
  <xref rid="bibr41-1759720X20912646" ref-type="bibr">41</xref>
 </sup>
</p>
